Sandra Beaver - 07 Mar 2025 Form 4 Insider Report for Evolus, Inc. (EOLS)

Reporting relationship: Chief Financial Officer
Issuer ticker: EOLS
Reported as of: 07 Mar 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Mar 2025, 18:54:54 UTC
Prior SEC filing: 26 Dec 2024
Next SEC filing: 20 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ Jeffrey J. Plumer, as attorney-in-fact for Sandra Beaver

Key filing fact

Sandra Beaver filed Form 4 for Evolus, Inc. (EOLS) on 11 Mar 2025.

Key facts

This page summarizes Sandra Beaver's Form 4 filing for Evolus, Inc. (EOLS).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 11 Mar 2025, 18:54.

Change

Previous filing in this sequence was filed on 26 Dec 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EOLS transaction

Common Stock

Award

Transaction value: $0
Shares: +35,663
Change %: +24%
Price: $0.000000
Shares after: 182,579
Date: 07 Mar 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EOLS transaction Derivative

Performance Restricted Stock Units

Award

Transaction value: $0
Shares: +35,663
Change %
Price: $0.000000
Shares after: 35,663
Date: 07 Mar 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 35,663
Exercise price
Footnotes: F2, F3

EOLS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +50,813
Change %
Price: $0.000000
Shares after: 50,813
Date: 07 Mar 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,813
Exercise price: $13.58
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest over a period of four years, with 1/4th of the RSU vesting annually on the anniversary of March 7, 2025, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.

Footnote F2

Each performance-based restricted stock unit ("PSU") represents the right to receive, following vesting, a number of shares of common stock of the issuer up to 200% of the number of PSUs.

Footnote F3

The number of shares of Common Stock acquired upon vesting of the PSUs is contingent upon the achievement of a preestablished performance metrics, as approved by the Issuer's Compensation Committee, over a two-year performance period. Subject to the Issuer's compensation committee certifying the underlying performance metrics, 100% of the PSUs will vest on March 7, 2028 in each case subject to time based service requirements and continuous employment with the Issuer through the vesting dates.

Footnote F4

The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting annually on the anniversary of March 7, 2025, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer.